{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.49"}]}],"title":"Participant 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.21"}]}],"title":"Participant 2"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"description":"Venous whole blood samples were collected for activity-based pharmacokinetics characterization in the dosimetry group. AUC(0-inf) was to be listed and summarized using descriptive statistics.","groups":[{"description":"All eligible participants were to receive recommended dose of \\[68Ga\\]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) \\[but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)\\].","id":"OG000","title":"Breast"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set (FAS). Dosimetry group targeted participants with Breast Cancer and Prostate Cancer, but only 2 participants from Breast Cancer arm enrolled in the Dosimetry Group. Due to the sample size in the dosimetry group (2 patients), summary statistics were not performed.","reportingStatus":"POSTED","timeFrame":"[68Ga]-NeoBOMB1 PET imaging acquired at Day 1","title":"Dosimetry Group: Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUCinf)","type":"SECONDARY","unitOfMeasure":"MBq-s/cc"}